Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy plus cisplatin and temozolomide for newly diagnosed primary glioblastoma
2008-000380-42Phase 2Completed
- Sponsor
- Carlo Besta Neurological Institute
- Start
- Jan 2009
- Modality
- Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of temozolomide and cisplatin in glioblastoma (GBM), sponsored by Carlo Besta Neurological Institute. Primary endpoint: Progression-free survival at 12 months. Started Jan 2009; status: completed.
02
Drugs
temozolomidecisplatin
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2008-000380-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000380-42.